Emibetuzumab, formerly known as LY2875358, represents a new treatment approach in oncology, specifically targeting the MET tyrosine enzyme. This engineered immunoglobulin operates by selectively binding to the MET receptor, inhibiting its engagement and subsequent downstream communication. Precli… Read More

Tralokinumab: Unveiling the Potential of LP 0162 and CAT-354 Tralokinumab, previously known as LP 0162 and CAT-354, represents a promising treatment for chronic dermatitis. This monoclonal antibody inhibits IL-13, a key driver involved in the progression of the disorder. Clinical tria… Read More

Tisotumab: A Research Tool for Antibody Studies Tiso was an important research method for investigating antibodies response. Specifically its unique composition allows investigators to explore features of immunoglobulin binding Tiso… Read More

Teclistamab stands as a revolutionary cutting-edge anti-BCMA antibody drug construct, designated JNJ-64007957, demonstrating immense promise in the treatment of multiple myeloma. This innovative therapeutic works by specifically attacking BCMA, a protein highly abundant on the surface of myelo… Read More